Relmada Therapeutics (RLMD) Depreciation & Amortization (CF) (2013 - 2021)

Relmada Therapeutics (RLMD) has 9 years of Depreciation & Amortization (CF) data on file, last reported at -$1.3 million in Q3 2021.

• Depreciation & Amortization (CF) for Q3 2021 came in at -$1.3 million, up 38.07% year-over-year; the trailing twelve-month figure through Jun 2022 was -$1.3 million (up 38.01% YoY), and the FY2021 annual result was $1258.0, down 66.47% from the prior year.
• Depreciation & Amortization (CF) retreated to -$1.3 million in Q3 2021 per RLMD's latest filing, from $452.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $23268.0 in Q1 2017 and troughed at -$2.1 million in Q3 2020.
• A 5-year average of -$185613.6 and a median of $926.0 in 2020 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2019 and 2020: Depreciation & Amortization (CF) soared 495.68% in 2019, then slumped 190742.82% in 2020.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $582.0 in 2017, then sank by 195.53% to -$556.0 in 2018, then soared by 495.68% to $2200.0 in 2019, then plunged by 62.59% to $823.0 in 2020, then tumbled by 157905.83% to -$1.3 million in 2021.
• Business Quant data shows RLMD's Depreciation & Amortization (CF) at -$1.3 million in Q3 2021, $452.0 in Q2 2021, and $806.0 in Q1 2021.